Tenecteplase is a form of recombinant tissue plasminogen activator (rtPA) used in the treatment of acute ischemic stroke (AIS), where it is used to dissolve blood clots that are causing the stroke. Tenecteplase is considered a 'third generation' thrombolytic agent, and is used in preference to the older agents because of its longer half-life, improved safety profile, and greater efficacy. Tenecteplase is usually administered as an intravenous injection into a vein, and is typically given within 4.5 hours of the onset of stroke symptoms. It has been shown to reduce the risk of death and disability due to stroke, although it is not suitable for everyone.
Tenecteplase is a medication used to treat a serious condition: acute myocardial infarction (AMI), also known as a heart attack. Here's a breakdown of its key functions:
Purpose:
- Dissolves blood clots that block coronary arteries during a heart attack.
- By dissolving the clot, Tenecteplase helps restore blood flow to the heart muscle, minimizing damage and potentially improving outcomes.
Mechanism of Action:
- Classified as a thrombolytic drug, often referred to as a "clot buster."
- Works by converting an inactive substance in the blood called plasminogen into its active form, plasmin.
- Plasmin is an enzyme that breaks down fibrin, the main protein component of blood clots.
- By dissolving the clot, Tenecteplase opens the blocked artery and allows blood to flow freely to the heart muscle.
Administration:
- Given as a single injection directly into a vein (intravenously) in a hospital setting.
- Timing is crucial for effectiveness, typically administered as soon as possible after the first signs of a heart attack appear.